Cargando…
Fumarate hydratase-deficient renal cell carcinoma: a case report and review of the literature
BACKGROUND: Fumarate hydratase-deficient renal cell carcinoma is a rare pathological subtype that was defined by the World Health Organization (WHO 5th edition) in 2022. At present, only a few hundreds of cases have been reported worldwide, mainly in Europe and the United States. A case of a Chinese...
Autores principales: | Lv, Yanting, Song, Lide, Hu, Mengjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116832/ https://www.ncbi.nlm.nih.gov/pubmed/37076922 http://dx.doi.org/10.1186/s13256-023-03841-0 |
Ejemplares similares
-
Fumarate hydratase-deficient renal cell carcinoma in extended remission with bevacizumab and erlotinib
por: Tomar, Shubham, et al.
Publicado: (2022) -
Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma
por: Lindner, Andrea Katharina, et al.
Publicado: (2022) -
Structural basis of fumarate hydratase deficiency
por: Picaud, Sarah, et al.
Publicado: (2011) -
Uterine leiomyoma with fumarate hydratase deficiency: A case report
por: Huang, Yan, et al.
Publicado: (2021) -
HIF and fumarate hydratase in renal cancer
por: Sudarshan, S, et al.
Publicado: (2007)